Donafenib Monotherapy for Previously Treated Metastatic Gastric Cancer
This open-label, one-center, noncomparative, two-stage phase 1B trial assessed the donafenib in advanced gastric cancer.
Gastric Cancer
DRUG: donafenib tosilate tablets
Number of Participants with Adverse Events, patients with adverse events/all patients\*100%, 54 weeks
Tumor response, complete response and partial response patients/all patients\*100%, 54 weeks|Progression-free survival time, median progress-free survival time, 54 weeks
This open-label, one-center, noncomparative, two-stage phase 1B trial assessed the tyrosine kinase inhibitor donafenib tosilate tablets (400 mg/d,200mg bid) in patients with advanced, inoperable gastric cancer progressing after chemotherapy . The primary endpoint is the safety.The secondary endpoints are tumor response and progression-free survival time.